Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review

Adam S. Komorowski1,2 | Helen J. MacKay3,4 | Rossanna C. Pezo3,4

1Division of Medical Microbiology, McMaster University, Hamilton, ON, Canada
2Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4Department of Medicine, University of Toronto, Toronto, ON, Canada

Correspondence
Rossanna C. Pezo, Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3N5. Email: rossanna.pezo@sunnybrook.ca

Funding information
Sunnybrook Research Institute; Sunnybrook Health Sciences Centre; University of Toronto

Abstract

Background: Clinical trial reports often emphasize efficacy over harms, leading to misinterpretation of the risk-to-benefit ratio of new therapies. Clear and sufficiently detailed reporting of methods and results is especially important in the abstracts of trial reports, as readers often base their assessment of a trial on such information. In this study, we evaluated the quality of adverse event (AE) reporting and abstract quality in phase III randomized controlled trials (RCTs) of systemic therapies in breast and colorectal cancer.

Methods: Medline, EMBASE, Cochrane Database of RCTs, and Cochrane Database of Systematic Reviews were searched from November 2005 to September 2018. Phase III RCTs evaluating systemic therapies in breast or colorectal cancer were included. Each article was independently reviewed by two investigators using a standardized data extraction form based on guidelines developed by the Consolidated Standards of Reporting Trials (CONSORT) group. Descriptive statistics, bivariate analysis, and multivariable linear regression were used to analyze data. All statistical tests were two-sided.

Results: Of 166 RCTs identified, 99.4% reported harms in the manuscript body, and 59.6% reported harms in the abstract. Reporting was restricted to severe harms in 15.6% of RCTs. Statistical comparison of AE rates went unreported in 59.0% of studies. Information regarding AEs leading to dose reductions, treatment discontinuations, or study withdrawals went unreported in 59.3%, 18.7%, and 86.8% of studies, respectively. Recently published RCTs (P = .009) and those sponsored at least partially by for-profit companies (P = .003) had higher abstract quality scores.

Conclusions: Breast and colorectal cancer phase III RCTs inadequately report CONSORT-compliant AE data. Improved guideline adherence and abstract reporting is required to properly weigh benefits and harms of new oncologic therapies.

Systematic Review Registration Number: CRD42019140673.

KEYWORDS
adverse events, breast neoplasms, colorectal neoplasms, CONSORT, drug-related side effects and adverse reactions, harms reporting, toxicities
1 | INTRODUCTION

Phase III randomized controlled trials (RCTs) assess the efficacy and harms of new treatment modalities in order to stringently determine their benefits and harms to patients. Accurate reporting is a necessary part of this determination: for example, inadequate reporting of adverse events (AEs) (harms) data can lead to misinterpretation of RCT results that may bias clinical decision-making.1-3

The treatment landscape in oncology has shifted away from the cyclical use of cytotoxic chemotherapies—typically associated with episodic, severe toxicities of short duration—toward continuously administered targeted treatments that may produce chronic, lower grade, and multi-organ system toxicities. As a result of increasingly long-term use of therapies, stringent AEs reporting has become more necessary. In addition, increasing sample sizes in oncologic RCTs of novel therapies has allowed the detection of smaller treatment effects4,5

The Consolidated Standards of Reporting Trials (CONSORT) statement was introduced in 2001 as a way to standardize reporting in RCTs.6 The CONSORT Harms Checklist was published in November 2004 to improve the reporting of AEs in order to foster both increased transparency and consistency of harms reporting in RCTs.7

In 2008, Hopewell et al published a CONSORT reporting checklist for RCT abstracts in the hopes of encouraging more stringent reporting of harms.8 This checklist takes into account the following: trial title, design description, eligibility criteria, interventions, specific hypothesis, primary outcome definition, description of randomization and blinding, number of patients randomized, trial status, number of patients analyzed, primary outcome effect size and precision, harms, general interpretation of the results, trial registration number, and source of funding. Seeing as many researchers glean trial information from an abstract, a clear set of harms reporting items specifically for abstracts is a vital extension of the CONSORT statement.6

Unfortunately, adherence to the CONSORT reporting items remains suboptimal to the present day. Pitrou et al examined the reporting of safety results from the general medical literature in 2009, finding that 27.1% of studies analyzed did not provide information on severe AEs, and 47.4% did not provide information on withdrawal of patients due to an AE.9 In the general medical literature, multiple studies have demonstrated that only half of phase III RCT abstracts report harms in an appropriate manner.10-12 This trend has been echoed in other specialties, including critical care.13 Examining metastatic solid tumor phase III RCT abstracts, Sivendran et al showed 74% reported serious or unexpected AEs,14 while Ghimire et al demonstrated a 77% adherence to harms reporting in oncology phase III RCT abstracts.15

The primary aim of this study was to systematically review and evaluate the quality of AE reporting in phase III breast and colorectal cancer RCTs. We also examined whether specific trial characteristics were associated with the quality of AE reporting, and could be predicted by an abstract quality score.

2 | MATERIALS AND METHODS

2.1 | Data sources

Medline, EMBASE, the Cochrane Database of Randomized Controlled Trials (CCRCT), and the Cochrane Database of Systematic Reviews (CDSR) were systematically searched in duplicate from November 2005 to 14 September 2018 using subject headings and keywords to capture breast cancer, colorectal cancer, AEs, and RCT terms (Breast Neoplasms; Colorectal Neoplasms; clinical trial, phase III; adverse drug reaction). The initial time point of November 2005 was chosen to capture studies published one calendar year after the introduction of the CONSORT AE reporting guidelines in November 2004. Subject headings and keywords were modified for each database according to its unique indexing terms. The search (Data S1) was conducted by a medical information specialist and limited to humans, with English language restrictions. Grey literature and reference lists of retrieved articles were also screened for additional relevant studies.

2.2 | Study selection

This review was conducted and reported according to PRISMA guidelines,16 and the study protocol was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42019140673). The aim of this review was to examine the quality of AEs reporting in phase III RCTs of systemic therapies in breast and colorectal cancer. Thus, all phase III RCTs evaluating drug regimens (chemotherapy, endocrine therapy, immunotherapy, and targeted agents) in breast cancer or colorectal cancer patients were included. Studies were excluded if the patient population did not include breast cancer or colorectal cancer patients; if trials were evaluating surgical or radiotherapeutic treatment modalities; or if duplicate data were reported. Phase I, II, and IV RCTs, editorials, commentaries, reviews, cohort studies, and case-control studies were excluded. Reference lists of excluded studies were screened to identify any potentially relevant studies. One reviewer (ASK) selected potentially eligible studies by independently screening titles and abstracts of identified studies. Full texts of the studies identified were subsequently retrieved and independently assessed for eligibility by one reviewer (ASK).
2.3 Data extraction

A data extraction form (Data S2) was developed based on the CONSORT Recommendations, as well as the CONSORT Harms Checklist.6,7 The form was modified from a previously published checklist used to evaluate the quality of harms reporting in the general medical literature.9 The data extraction form was designed to capture information from the both the abstract and the entire clinical trial report, and was divided into the following sections: methodology, sponsorship, results, reporting of AEs, reporting of severity, reporting of need for treatment discontinuations (TDs) and dose reductions (DRs), and reporting of statistical tests for AEs. AE data described in appendices or supplementary files were considered to be part of the “full text” of the included studies for the purposes of this review. Data were extracted independently by two reviewers (ASK and RCP).

During data extraction, an abstract quality score was assigned to each publication that took into account the following reporting items: explanation of study rationale; brief description of participants; description of intervention; explicit statement of primary endpoint; duration of follow-up; reporting of planned sample size; p-value or confidence interval reporting; description of AEs or toxicities; and specification of funding source.

2.4 Risk of bias assessment

The Cochrane Risk of Bias Tool for Randomized Controlled Trials 2.0 (RoB 2.0) was deemed appropriate for use in assessing the included studies, given that the studies under systematic review were RCTs. The RoB 2.0 rates studies as “low risk”, “unclear risk”, or “high risk” of bias using pre-established criteria to evaluate both study design and applicability.17 Risk of bias was determined by a single reviewer (ASK).

2.5 Primary and secondary outcomes

The primary outcome was the evaluation of the quality of AE reporting according to the percentage of trials including detailed information on AEs (reporting of AEs in figure/table vs only text, per treatment arm, separation of expected/unexpected AEs, and scale used for AE severity) of dose reduction and treatment discontinuations in phase III RCTs of breast and colorectal cancer treatment regimens. The secondary outcome was based on an exploratory analysis of trial characteristics, with the aim of determining whether specific trial characteristics were associated with the quality of the abstract, as represented by a numerical score assigned during data extraction (see “Materials and Methods—Data Extraction”).

2.6 Statistical analysis

Statistical analysis was performed by a biostatistician using SAS 9.4 (Cary, SAS Institute). Descriptive statistics, including mean and standard deviation, were used for continuous variables, whereas categorical variables were described with frequencies and percentages and compared using the chi-squared test. All statistical tests were two-sided, and statistical significance was defined as \( P < .05 \). Bivariate linear analysis was used to examine the association between the abstract quality score assigned during data extraction and selected trial characteristics. Significant covariates found during bivariate analysis were used to run the multivariable linear regression model. Multivariable linear regression analysis was thus used to identify trial characteristics associated with inadequate safety reporting. Given the lack of sufficient homogeneity between included studies with regards to participants, interventions, and outcomes, a meaningful summary statistic could not be calculated; the clinical and methodological heterogeneity obviated the use of meta-analysis on these studies.

3 RESULTS

3.1 Study characteristics

The literature search yielded 2034 abstracts; an additional 20 studies were identified through grey literature searches. After removal of duplicates and assessment by reviewers, 201 full texts were assessed for inclusion. 35 full texts were excluded from analysis, with reasoning provided in Data S3. Ultimately, 166 studies were included in this systematic review (Figure 1).18-183 Characteristics of included studies are summarized in Table 1, whereas the complete set of consensus extracted data may be found in Data S4A (the data extraction set of Reviewer 1 is found in Data S4B, and the data extraction set of Reviewer 2 is found in Data S4C). All studies were published on or after November 2005, inclusive. The included studies cover each year of the date range captured by the search strategy, and represent diverse patient populations from North America, Europe, Asia, and Australia. Of the included studies, 121 (72.9%) evaluated any-stage breast cancer, whereas 45 (27.1%) evaluated any-stage colorectal cancer. Eighteen studies (10.8%) investigated neoadjuvant treatment regimens, whereas 51 (30.7%), 54 (32.5%), and 43 (25.9%) studies evaluated adjuvant, first-line metastatic, and ≥second-line metastatic treatment regimens, respectively. The median sample size of included studies was 627 patients (range: 51-9779). A total of 138 included studies (83.1%) were at least partially funded by industry; however, only 38 studies (22.9%) explicitly stated provision of study drug by a for-profit sponsor.
3.2 Safety reporting

The main results of the harms reporting analysis are described in Table 2. Of the studies examined, 165 (99.4%) reported AEs in the body of the manuscript, and the majority of reports had at least one table/figure to report AEs (n = 159, 95.8%). While most (n = 162, 97.6%) manuscripts described AEs per arm, four included studies described AEs in only one arm. Severe AEs (typically greater than grade 3 on the Common Terminology Criteria for Adverse Events scale) were the sole reported type of AE in 26 studies (15.6%). Notably, a majority of studies (n = 98, 59.0%) did not perform a statistical comparison of AE rates between study arms.

A scale for severity grading of AEs was identified in 91.5% (n = 152) of trials. The most commonly used scale—in 143 trials (86.1%)—was the Common Terminology Criteria for Adverse Events (CTCAE). A small number of trials (n = 14, 8.4%) omitted a severity scale or failed to report which scale was used. Notably absent from many of the included studies was information on AEs leading to dose reductions, treatment discontinuations, study withdrawal, or death. AEs leading to dose reduction or treatment discontinuation went unreported in 59.3% and 18.7% of studies, respectively. AEs leading to study withdrawal were not reported in 86.8% of studies, and no information on deaths due to AEs was reported in 34.6% of trials.
Abstract quality scoring

Linear regression of exploratory variables using abstract quality score as the dependent variable identified several significant trends outlined in Tables 3 and 4.

The results of bivariate analysis demonstrated that a recent year of publication was significantly associated with a high-abstract quality score ($\beta = 0.096, t = 3.61, P = .0004$). In addition, the provision of the study drug by a for-profit sponsor was significantly associated with a high-abstract quality score ($\beta = 0.56, t = 2.48, P = .014$).

The overall model fit for the final multivariable regression equation was $R^2 = 0.14$. Papers published in recent years had significantly higher abstract quality scores ($P = .009$). Compared with papers that received nonprofit sponsorship, those with either for-profit ($P = .002$) or mixed sponsorship ($P = .003$) had significantly higher abstract quality scores. There was no statistically significant difference between the abstract quality scores of breast and colorectal cancer RCTs that were investigating curative vs palliative treatment regimens ($P = .10$).

Risk of bias

Of the included studies ($n = 166$), 164 were analyzed for risk of bias using the RoB 2.0 intention-to-treat checklist, while two papers were analyzed using the per-protocol checklist.
Of the 164 intention-to-treat studies, 49.4% were deemed overall to have a low risk of bias, 27.4% were deemed to have an unclear risk of bias, and 20.1% were deemed to have a high risk of bias. (Figure 2)(For the complete risk of bias data, see Data S5).

Of the two per-protocol studies, one had an unclear risk of bias, and one had a high risk of bias. Both studies had a low risk of bias in the “randomization process” and “missing outcome data” domains; both studies had an unclear risk of bias in the “deviation from intended interventions” domain; 50% had a low, and 50% had an unclear, risk of bias in the “outcome measurement” domain; finally, 50% had a low, and 50% had a high risk of bias in the “selection of reported result” domain.

### DISCUSSION

In this systematic review, we evaluated the quality of AE reporting according to the CONSORT guidelines in phase III RCTs of drug regimens in breast and colorectal cancer patients between November 2005 and September 2018. Most studies do not adequately report harms as per the CONSORT guidelines. Although virtually all studies analyzed reported AEs in the main manuscript text ($n = 165, 99.4$%), 40.4% of reports either inadequately reported or did not include harms-related results in the study abstract. A 2009 analysis of trial abstracts by Berwanger et al in four major medical journals found that only half reported AE data in their abstracts.10

Another study in 2013 reiterated the finding of substandard AE reporting, with only 32% of breast cancer RCT abstracts adequately reporting harms.184 The CONSORT authors and other groups have acknowledged the utility of stating AEs in phase III RCT abstracts: this data is important for not only establishing databases, but also retrieving appropriate information used in clinical decision-making.7,185

Severe AEs (typically greater than grade 3 on the Common Terminology Criteria for Adverse Events scale) were the sole reported type of AE in 26 studies (15.6%). Lower grade toxicities that are persistent over a prolonged period may be intolerable for patients if they have a negative impact on quality of life. For example, small molecule inhibitors—which are often offered in daily dosage regimens for some cancers—and the presence of chronic, low-grade toxicities, may limit adherence to these treatments in routine practice. A lack of adherence to therapy would minimize the benefits observed in RCTs. Indeed, studies themselves may select for patient populations that underemphasize the impact of low-grade toxicities: eligible patients for RCTs typically have fewer comorbidities and higher performance statuses. Furthermore, the supportive care available to study patients may help mitigate the impact of low-grade AEs on quality of life in a way that is not reproducible in routine practice. For example, clinical trial nurses, dosing diaries, structured dose modification criteria, and trial educational materials/programs all offer support outside typical practice norms. Thus, the sole reporting of severe AEs may severely limit the ability of oncologists to provide appropriate counsel to patients, mitigating their ability to provide supportive care when needed.

Among the studies we systematically reviewed, reporting of dose modification due to AEs was poor: dose reductions went unreported in 59.3%. These high figures represent a key flaw in the way most studies report their findings. Accurate reporting of dose reductions is important; it reflects whether the starting dose that is chosen for a RCT is appropriate and tolerable. An investigational agent that may be associated with few grade 3 or higher toxicities—but frequent low-grade toxicities—may not be tolerable with prolonged administration. The recommended phase II dose (RP2D) and schedule of administration for an investigational agent is established during dose escalation phase I trials. There are a limited number of patients treated at the RP2D during
phase I/II trials: these patients may not reflect the patient population enrolled in an RCT, or those who are treated outside of clinical trials in routine practice once an investigational agent has been approved by a regulatory body. Patients enrolled in phase I/II studies usually have advanced disease previously treated with multiple lines of prior therapy; they may only be treated an investigational agent for a short period of time, usually less than 6 months, and may be more willing to accept low-grade toxicities that patients exposed to few lines of therapy, or with early stage disease treated in the adjuvant setting. In addition, phase I/II trials are usually performed by a small number of investigators who may be more experienced with toxicity management than phase III RCTs. In the adjuvant setting, patients may be less tolerable of low-grade toxicities. Furthermore, for the palliative

| Trial characteristic | Abstract quality score (0-10) | Regression analysis | Regression coefficient estimate | t | P  | Regression coefficient estimate | t | P  |
|----------------------|-----------------------------|--------------------|--------------------------------|---|----|--------------------------------|---|----|
|                      |                             | Bivariate analysis | Multivariable analysis         |
|                      | Mean | Regression coefficient estimate | t | P  | Mean | Regression coefficient estimate | t | P  |
| Year of publication, continuous | 6.8 | .09604 | 3.61 | .0004 | 6.8 | .09604 | 3.61 | .0004 |
| Results of primary outcome |                |                |                |                |                |                |                |                |
| Negative | 7.1 | −.115 | −0.58 | .5645 | Not investigated in model |
| Positive | 7.2 | n/a | n/a | n/a | Not investigated in model |
| Sponsorship |                |                |                |                |                |                |                |                |
| Non-industry | 6.9 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Industry | 7.3 | .78786 | 3.03 | .0028 | .82252 | 3.17 | .0019 |
| Mixed | 7.5 | .97838 | 3.23 | .0015 | .88939 | 3.01 | .0031 |
| Intent of study therapy |                |                |                |                |                |                |                |                |
| Curative | 7.2 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Palliative | 7.1 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Tumor site |                |                |                |                |                |                |                |                |
| Breast | 7.2 | n/a | n/a | n/a | Not investigated in model |
| Colorectal | 7.1 | −.1107 | −0.51 | .6139 | Not investigated in model |
| Line of therapy |                |                |                |                |                |                |                |                |
| Neoadjuvant | 6.9 | 7.33721 | −1.12 | .2627 | Not investigated in model |
| Adjuvant | 7.4 | .55495 | 0.21 | .8314 | Not investigated in model |
| Metastatic, first line | 6.9 | −.402 | −1.58 | .116 | Not investigated in model |
| Metastatic, ≥ second line | 7.3 | n/a | n/a | n/a | Not investigated in model |
| Type of investigational therapy |                |                |                |                |                |                |                |                |
| Cytotoxic chemotherapy | 7.0 | −.0214 | −0.07 | .9475 | Not investigated in model |
| Endocrine therapy | 7.0 | −.0487 | −0.12 | .9031 | Not investigated in model |
| Targeted therapy | 7.8 | .76711 | 1.92 | .056 | Not investigated in model |
| Combination cytotoxic chemotherapy and endocrine therapy | 7.0 | −.075 | −0.1 | .9227 | Not investigated in model |
| Combination cytotoxic chemotherapy and targeted therapy | 7.2 | .10867 | 0.33 | .7429 | Not investigated in model |
| Other | 7.1 | n/a | n/a | n/a | Not investigated in model |
management of metastatic disease, the burden of harm and its often profound impact on quality of life must be balanced against improvements in disease-related symptoms and survival.

TABLE 4  Overall P-values for regression analyses of trial characteristics predictive of abstract quality score

| Trial characteristic                  | Overall P-values | Bivariate analysis | Multivariable analysis |
|--------------------------------------|------------------|-------------------|------------------------|
| Intent of study therapy              | .0034            | 0.0040            |                        |
| Line of therapy                      | .1386            | Not investigated in model |                      |
| Type of investigational therapy      | .2724            | Not investigated in model |                      |

Less than half (41.0%) of the RCTs examined included statistical comparisons of AEs between treatment arms. In addition, many studies did not identify the population used for safety analysis. Identifying the population used for safety analysis is likewise necessary, as the exclusion of any treated patients could bias the interpretation of harms-related reporting.

Similar findings to those observed in our study of breast and colorectal cancer RCTs have been reported in other medical disciplines. In the general medical literature, Pitrou et al found that 18% of reports did not describe AEs with numerical data, and that information relating to the withdrawal of patients due to AEs was missing in 47% of papers.9 In our study, we found that 18.7% of papers did not give information on the need to discontinue treatment due to AEs, whereas data on patient withdrawal due to AEs were missing in 86.8% of papers. Our study was also concordant with analyses in the oncology literature: for example, a 2016 paper
by Maillet et al that reviewed oncology RCTs between 2007 and 2011 indicated that frequency and nature of grade 5 AEs were adequately reported in 50%, AEs leading to study withdrawal in 19%, and AEs leading to dose reduction in 13% of manuscripts.186

Using bivariate and multivariable linear regression in an exploratory analysis, we examined whether any study characteristics were associated with the abstract quality scores we assigned during data extraction. Both bivariate and multivariable analyses showed that a recent year of publication was associated with a higher abstract quality score ($P = .009$, multivariable model).

We also examined whether industry-sponsored studies had better reporting of AEs. An earlier study from the neurology literature of antiepileptic RCTs described a poor quality of AE reporting187 with improved safety reporting in studies sponsored by for-profit companies, compared with studies having an academic hospital or cooperative group sponsor. Our study similarly found that industry-sponsored studies tended to have improved AE reporting than those sponsored by nonprofit groups: those with either for-profit ($P = .002$) or mixed sponsorship ($P = .003$) had significantly higher abstract quality scores. This may be due to the added costs of collecting detailed data on AEs, or possibly as a result of guidelines on data collection and reporting in pharmaceutical-sponsored studies.

4.1 | Limitations

A limitation of this study was that the search strategy was limited to English-language publications; however, as there were no other restrictions and a large number of studies were included, this is unlikely to compromise this review’s integrity. Overall, selection and performance biases were moderate across studies, while detection and attrition biases were generally low. The impact of selection and performance biases on the conclusions of this review is minimized by restricting the multivariable analysis to determining how well study abstracts report AEs data. A further limitation of this study is the lack of analysis of quality of life data which would allow situating our study more deeply in the patient-centric experience.

5 | CONCLUSION

Our systematic review highlights the incomplete reporting of harms in breast and colorectal cancer RCTs. A more complete description of harms is needed in order to better understand the therapeutic index of new treatments. We propose that adherence to the CONSORT AE statement should be a mandatory requirement of phase III RCT publication in medical journals, in order to ensure consistent reporting of harms data across trials. With the increasing use of immunotherapies and targeted therapies, oncologic RCTs in general may also require additional standards for the reporting of low-grade toxicities that lead to dose interruptions, dose reductions, and treatment discontinuations. Such reporting standards may help indicate the tolerability of investigational agents administered over a long period of time and would move the RCT investigational paradigm closer to a more holistic, patient-centered view of clinical outcomes.

ACKNOWLEDGMENTS

The authors thank Xingshan Cao at the Institute for Clinical Evaluative Sciences at the University of Toronto for his expert help in statistical analysis.

CONFLICT OF INTEREST

The authors report no relevant conflicts of interest.

AUTHOR CONTRIBUTIONS

Conception, design, collection of data, analysis, interpretation: ASK and RCP; writing, review and revision of manuscript: ASK and RCP. Funding acquisition and oncology expertise: HJM and RCP.

DATA AVAILABILITY STATEMENT

Source data are available from the corresponding author on reasonable request.

ORCID

Rossanna C. Pezo https://orcid.org/0000-0002-1260-7710

REFERENCES

1. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet. 1998;352:1752-1753.
2. Ioannidis JP, Lau J. Completeness of safety reporting in randomised trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-443.
3. Loke YK, Derry S. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. BMC Clin Pharmacol. 2001;1:3.
4. Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK. Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol. 2008;26:5458-5464.
5. Seruga B, Hertz PC, Wang L, et al. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol. 2010;21:1411-1418.
6. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134:657-662.
7. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781-788.
8. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. *PLoS Med.* 2008;5:e20.

9. Pitrou I, Boulton I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. *Arch Intern Med.* 2009;169:1756-1761.

10. Berwanger O, Ribeiro RA, Finkelstein A, et al. The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals. *J Clin Epidemiol.* 2009;62:387-392.

11. Hays M, Andrews M, Wilson R, Callender D, O'Malley PG, Douglas K. Reporting quality of randomised trial abstracts among high-impact general medical journals: a review and analysis. *BMJ Open.* 2016;6:e011082.

12. Ghimire S, Kyung E, Kang W, Kim E. Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals. *Trials.* 2012;13:77.

13. Kuriyama A, Takahashi N, Nakayama T. Reporting of critical care trial abstracts: a comparison before and after the announcement of CONSORT guideline for abstracts. *Trials.* 2017;18:32.

14. Sivendran S, Newport K, Horst M, Albert A, Galsky MD. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. *Trials.* 2015;16:341.

15. Ghimire S, Kyung E, Lee H, Kim E. Oncology trial abstracts showed suboptimal improvement in reporting: a comparative before-and-after evaluation using CONSORT for Abstract guidelines. *J Clin Epidemiol.* 2014;67:658-666.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med.* 2009;151:264-269, w264.

17. Higgins JPT, Savović JAC, Page MJ, et al. A revised tool for assessing risk of bias in randomized trials. *Cochrane Database Syst Rev.* 2016;10(Suppl 1):29-31.

18. Adjuvant Breast Cancer Trials Collaborative G. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. *J Natl Cancer Inst.* 2007;99:506-515.

19. Adjuvant Breast Cancer Trials Collaborative G. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. *J Natl Cancer Inst.* 2007;99:516-525.

20. Aebi SOS, Anderson S, Lang J, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *The Lancet.* 2014;15:156.

21. Alhara T, Takatsuka Y, Ohsumi S, et al. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. *Breast Cancer Res Treat.* 2010;121:379-387.

22. Amadori D, Silvestrini R, De Lena M, et al. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer. *Breast Cancer Res Treat.* 2011;125:775-784.

23. André F, O'Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol.* 2014;15:580.

24. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2014;15:1065-1075.

25. Aparicio T, Lavau-Denes S, Philip J, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). *Ann Oncol.* 2016;27:121-127.

26. Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEHERT-r randomized clinical trial. *JAMA Oncol.* 2016;2:1557-1564.

27. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2012;379:633-640.

28. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med.* 2012;366:520-529.

29. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017;18:904-916.

30. Baselga J, Manikhas A, Cortés J, et al. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. *Ann Oncol.* 2014;25:592.

31. Baselga J, Zamagni C, Gómez P, et al. RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capcitabine versus placebo with capcitabine in locally advanced or metastatic HER2-negative breast cancer. *Clin Breast Cancer.* 2017;17:585.

32. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med.* 2012;366:310-320.

33. Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. *J Clin Oncol.* 2012;30:921.

34. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. *J Clin Oncol.* 2012;30:1919.

35. Big 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. *N Engl J Med.* 2005;353:2747-2757.

36. Bruksky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol.* 2011;29:4286.

37. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol.* 2013;14:933-942.
38. Cameron D, Morden JP, Canney P, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. *Lancet Oncol*. 2017;18:929-945.

39. Cascinu S, Rosati G, Nasti G, et al. Treatment sequence with either irinotecan/celecoxib followed by FOLFIRI-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: an Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. *Eur J Cancer*. 2017;83:106-115.

40. Cashin PH, Mahteme H, Spang N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. *Eur J Cancer (Oxford, England)*. 2016;53:155-162.

41. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab as adjuvant therapy in HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2016;17:367-377.

42. Chan S, Romeieu H, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. *J Clin Oncol*. 2009;27:1753.

43. Chang W, Wei Y, Ren L, et al. Randomized controlled trial of combination chemotherapy for the treatment of metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: an Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. *Eur J Cancer*. 2017;83:106-115.

44. Chen J, Yao Q, Huang M, et al. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRTO1). *Int J Cancer*. 2018;142:2130-2138.

45. Chen X, Ye G, Zhang C, et al. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer. *Breast Cancer Res Treat*. 2013;142:549.

46. Cortes J, Perez-Garcia J, Levy C, et al. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer. *Ann Oncol*. 2018;29:881-887.

47. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet (London, England)*. 2011;377:914.

48. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. *Lancet Oncol*. 2012;13:1225-1233.

49. Del Mastro L, Levaggi A, Michelotti A, et al. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIGS trial. *Breast Cancer Res Treat*. 2016;155:117-126.

50. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase iii trial. *J Clin Oncol*. 2016;34:3300-3307.
in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-4625.
65. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
66. Gianni L, Mansutti M, Anton A, et al. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial. JAMA Oncol. 2018;4:302-308.
67. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
68. Gilgorev J, Doval D, Bines J, et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1351-1360.
69. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2015;33:3638-3646.
70. Goss PE, Ingle JN, Pritchard KL, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209-219.
71. Goss PE, Smith IE, O'Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:88-96.
72. Grothey A, Van Cutsem E, Sobero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013;381:303-312.
73. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013;31:1947.
74. Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase IIIa trial. Chin J Cancer. 2011;30:682-689.
75. Hagman H, Frodin JE, Berglund A, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol. 2016;27:140-147.
76. Hamaguchi T, Shimada Y, Mizusawa J, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3:47.
77. Harbeck N, Huang CS, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX- Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016;17:357-366.
78. Harbeck N, Saue S, Jäger E, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017;161:63.
breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. *Lancet Oncol.* 2013;14:989-998.

93. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. *J Clin Oncol.* 2006;24:5381-5387.

94. Jonker DJ, Nott L, Yoshino T, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. *The Lancet. Gastroenterol Hepatol.* 2018;3:263-270.

95. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of post-menopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study. *J Clin Oncol.* 2009;27:5529.

96. Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol.* 2015;33:594.

97. Kaufmann M, Graf E, Jonat W, et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)—the German Adjuvant Breast Cancer Group. *J Clin Oncol.* 2005;23:7842-7848.

98. Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine for bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2016;17:1543-1557.

99. Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating paclitaxel plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. *Br J Cancer.* 2016;115:1206-1214.

100. Kimura M, Tominaga T, Kimijima I, et al. Phase III randomized trial of toremifene versus tamoxifen for Japanese post-menopausal patients with early breast cancer. *Breast Cancer.* 2014;21:275-283.

101. Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2014;15:689-699.

102. Kummel S, Kroker J, Kohls A, et al. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. *Br J Cancer.* 2006;94:1237-1244.

103. Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. *Ann Oncol.* 2017;28:1288-1293.

104. Langley RE, Carmichael J, Jones AL, et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J Clin Oncol.* 2005;23:8322-8330.

105. Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. *JAMA.* 2018;319:2486-2496.

106. Li J, Xu R, Qin S, et al. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized phase III study. *Cancer Medicine.* 2018;14:2031-2044.

107. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med.* 2018;379:753-763.

108. Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNeSS): a randomised, phase 3 trial. *Lancet Oncol.* 2018;19:497-509.

109. Lorusso V, Giotta F, Bordonaro R, et al. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: a multicenter phase III study. *Int J Oncol.* 2014;45:2137.

110. Loupakis F, Cremoni C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med.* 2014;371:1609-1618.

111. Lück HJ, Du Bois A, Loibl S, et al. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. *Breast Cancer Res Treat.* 2013;139:779.

112. Lück HJ, Lübbe K, Reinsch M, et al. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. *Breast Cancer Res Treat.* 2015;149:141.

113. Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. *Ann Oncol.* 2016;27:1074-1081.

114. Mackey R Jr, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line doctetaxel chemotherapy in metastatic breast cancer. *J Clin Oncol.* 2015;33:1341.

115. Margolese RG, Cucchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. *Lancet (London, England).* 2016;387:849-856.

116. Martin M, Campone M, Bondarenko I, et al. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. *Ann Oncol.* 2018;29:1195-1202.

117. Martin M, Ruiz A, Borrego MR, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. *J Clin Oncol.* 2013;31:2593-2599.

118. Martin M, Segui MA, Anton A, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. *N Engl J Med.* 2010;363:2200-2210.

119. Sanofi P, Also A. Epirubicin plus cyclophosphamide and doxorubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. *J Clin Oncol.* 2015;33:3788.

120. Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med.* 2017;376:2147-2159.
121. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2012;13:345.

122. Mavroudis D, Matikas A, Malamos N, et al. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). *Ann Oncol*. 2016;27:1873-1878.

123. Miller K, Wang M, Gralew J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med*. 2007;357:2666-2676.

124. Miller KD, O’Neill A, Gradishar W, et al. Double-blind phase III trial of adjuvant chemotherapy with or without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103). *J Clin Oncol*. 2018;36:2621-2629.

125. Miyake Y, Nishimura J, Kato T, et al. Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSCO-CCTG). *Surg Today*. 2017;48(1):66-72.

126. Mobus V, von Minckwitz G, Jackisch C, et al. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. *Ann Oncol*. 2017;28:1803-1810.

127. Morales L, Canney P, Dyczka J, et al. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. *Eur J Cancer*. 2007;43:331-340.

128. Oki E, Murata A, Yoshida K, et al. A Randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). *Ann Oncol*. 2016;27:1266-1272.

129. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2014;371:107.

130. Park IH, Sohn JH, Kim SB, et al. An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. *Cancer Res Treat*. 2017;49:569-577.

131. Peeters M, Price TJ, Bondarenko I, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALICON): an international, randomised, double-blind, phase 3 trial. *The Lancet*. 2016;388:2997-3005.

132. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. *J Clin Oncol*. 2018;36:968-974.

133. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECTCCT): a randomized, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncol*. 2014;15:569-579.

134. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. *J Clin Oncol*. 2016;34:1034-1042.

135. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with neoadjuvant therapy for human epidermal growth factor receptor 2-positive early breast cancer. *J Clin Oncol*. 2016;34:1034-1042.

136. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECTCCT): a randomized, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncol*. 2014;15:569-579.

137. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALICON): an international, randomised, double-blind, phase 3 trial. *The Lancet*. 2016;388:2997-3005.

138. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med*. 2017;377:523-533.

139. Rochlitz C, Bigler M, von Moos R, et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capetitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. *BMC Cancer*. 2016;16:780.

140. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients With ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. *JAMA*. 2017;317:37-47.

141. Schipper W, Samonigg H, Schaberl-Moser R, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluouracil and leucovorin in patients with stage II colon cancer. *Br J Cancer*. 2007;97:1021-1027.

142. Schmid P, Untch M, Kosse V, et al. Leuprolrelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. *J Clin Oncol*. 2007;25:2509-2515.

143. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). *J Clin Oncol*. 2012;30:3588-3595.

144. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. *Oncologist*. 2010;15:122.

145. Seidman A, Brufsky A, Ansari RH, et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. *Ann Oncol*. 2011;22:1094.

146. Siu LL, Shapiro JD, Jonker DJ, et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. *Ann Oncol*. 2011;22:1094.

147. Slade G, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/
HER2—advanced breast cancer who had progressed while receiving endocrine. *Therapy.* 2017;35:2875-2884.

148. Smith I, Yardley D, Burris H, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal women with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. *J Clin Oncol.* 2017;35:1041-1048.

149. Sparano J, Makhson AN, Semiglavzov VF, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. *J Clin Oncol.* 2009;27:4522.

150. Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. *Lancet Oncol.* 2017;18:917-928.

151. Steger GG, Greil R, Lang A, et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSD-24). *Ann Oncol.* 2014;25:366-371.

152. Taieb J, Tabernero J, Mini E, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014;15:862.

153. Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol.* 2016;17:90.

154. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. *J Clin Oncol.* 2007;25:5210-5217.

155. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med.* 2009;360:563-572.

156. Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol.* 2014;15:862.

157. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol.* 2017;18:904-915.

158. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol.* 2017;18:904-915.

159. Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med.* 2015;373:209.

160. Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. *Lancet Oncol.* 2016;17:345-356.

161. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol.* 2007;25:1658-1664.

162. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomised clinical trial. *JAMA.* 2017;317:2392-2401.

163. Venske NA, Heinekk M, Sharma N, et al. SIRLOX: randomised phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. *J Clin Oncol.* 2016;34:1723-1731.

164. Venske NA, Heinekk M, Sharma N, et al. SIRLOX: randomised phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. *J Clin Oncol.* 2016;34:1723-1731.
175. Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. *Oncology (Switzerland).* 2013;85:328-335.

176. Yamamoto D, Sato N, Tai Y, et al. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomised phase III JO21095 trial. *Breast Cancer Res Treat.* 2017;161:473-482.

177. Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). *Ann Oncol.* 2016;27:1539-1546.

178. Yardley DA, Arrowsmith ER, Daniel BR, et al. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. *Breast Cancer Res Treat.* 2017;164:649-658.

179. Zdenkowski N, Forbes JF, Boyle FM, et al. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. *Ann Oncol.* 2016;27:806-812.

180. Zhang M, Wei W, Liu J, et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. *Onco Targets Ther.* 2016;9:3443-3450.

181. Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. *Lancet Oncol.* 2017;18:371-383.

182. Zhou Y, Ouyang T, Xie Y, et al. A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer. *Breast Cancer Res Treat.* 2016;157:527-534.

183. Zielinski C, Lang I, Inbar M, et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. *Lancet Oncol.* 2016;17:1230-1239.

184. Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF. Bias in reporting of end points of efficacy and toxicity in randomised, clinical trials for women with breast cancer. *Ann Oncol.* 2013;24:1238-1244.

185. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. *BMC Med Res Methodol.* 2001;1:7.

186. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Peron J. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. *Ann Oncol.* 2016;27:192-198.

187. Shukralla AA, Tudur-Smith C, Powell GA, Williamson PR, Marson AG. Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms. *Epilepsy Res.* 2011;97:20-29.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

**How to cite this article:** Komorowski AS, MacKay HJ, Pezo RC. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. *Cancer Med.* 2020;9:5035–5050. [https://doi.org/10.1002/cam4.3095](https://doi.org/10.1002/cam4.3095)